Scarica l'app Stockscreener
0.68
5.38%
-0.0387
Dopo l'orario di chiusura:
.70
0.02
+2.94%
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - The Manila Times
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym - StreetInsider
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - Investing News Network
Tenaya to present gene therapy trial data Wednesday By Investing.com - Investing.com South Africa
Tenaya to present gene therapy trial data Wednesday - Investing.com
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya director granted options for 120,000 shares | TNYA Insider Trading - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) awards director 120,000 options at $0.7989 - Stock Titan
Tenaya (TNYA) director receives 120K stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) director June Lee granted 120,000 stock options - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options grant - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) boosts share pool in revised equity plan - Stock Titan
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 - Investing News Network
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference on May 29, 2026 - geneonline.com
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026 in June - Pluang
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 - Quiver Quantitative
Tenaya Therapeutics Q1 2026 Earnings: Narrow Miss on Earnings as Biotech Firm Reports No RevenueEPS Miss Report - newsline.com
What do we know so far from TN-201 trial? - Moomoo
TN-201 and TN-401 - Moomoo
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com India
Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):